The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity
Open accessAbstract
Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) tract expansion near the N terminus of huntingtin (Htt). Proteolytic processing of mutant Htt and abnormal calcium signaling may play a critical role in disease progression and pathogenesis. Recent work indicates that calpains may participate in the increased and/or altered patterns of Htt proteolysis leading to the selective toxicity observed in HD striatum. Here, we identify two calpain cleavage sites in Htt and show that mutation of these sites renders the polyQ expanded Htt less susceptible to proteolysis and aggregation, resulting in decreased toxicity in an in vitro cell culture model. In addition, we found that calpain- and caspase-derived Htt fragments preferentially accumulate in the nucleus without the requirement of further cleavage into smaller fragments. Calpain family members, calpain-1, -5, -7, and -10, have increased levels or are activated in HD tissue culture and transgenic mouse models, suggesting they may play a key role in Htt proteolysis and disease pathology. Interestingly, calpain-1, -5, -7, and -10 localize to the cytoplasm and the nucleus, whereas the activated forms of calpain-7 and -10 are found only in the nucleus. These results support the role of calpain-derived Htt fragmentation in HD and suggest that aberrant activation of calpains may play a role in HD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Yuan, J. (1993) · Cell · doi:10.1016/0092-8674(93)90485-9 · Cited by 2,483
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
Horikawa, Y., Oda, N., Cox, N. J., Li, X., Orho-Melander, M., Hara, M., Hinokio, Y., Lindner, T. H., Mashima, H., Schwarz, P. E. H., et al. (2000) · Nature Genetics · doi:10.1038/79876 · Cited by 1,468
Cross-Talk between Two Cysteine Protease Families
Nakagawa, T., & Yuan, J. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.4.887 · Cited by 1,168
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Self-citationAtaxin-1 Nuclear Localization and Aggregation
Klement, I. A., Skinner, P. J., Kaytor, M. D., Yi, H., Hersch, S. M., Clark, H. B., Zoghbi, H. Y., & Orr, H. T. (1998) · Cell · doi:10.1016/s0092-8674(00)81781-x · Cited by 956
Calpain and caspase: can you tell the difference?
Wang, K. K. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01479-4 · Cited by 912
Calcium-activated neutral protease (calpain) system: structure, function, and regulation.
Croall, D. E., & DeMartino, G. N. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.3.813 · Cited by 833
Cited by
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway
Williams, A., Sarkar, S., Cuddon, P., Ttofi, E. K., Saiki, S., Siddiqi, F. H., Jahreiss, L., Fleming, A., Pask, D., Goldsmith, P., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.79 · Cited by 800
“One possibility is that calpains enhance mutant huntingtin cleavage and processin”
BackgroundNormal huntingtin function: an alternative approach to Huntington's disease
Cattaneo, E., Zuccato, C., & Tartari, M. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1806 · Cited by 657
Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2006.04.026 · Cited by 651
Self-citationAberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Sathasivam, K., Neueder, A., Gipson, T. A., Landles, C., Benjamin, A. C., Bondulich, M. K., Smith, D. L., Faull, R. L. M., Roos, R. A. C., Howland, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221891110 · Cited by 528
Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines, R. M., Boyd, J. D., Ko, R. W. Y., Vasuta, O. C., Graham, R. K., Hayden, M. R., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.008 · Cited by 517
Self-citationHuntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Regulating cell migration: calpains make the cut
Franco, S. J., & Huttenlocher, A. (2005) · Journal of Cell Science · doi:10.1242/jcs.02562 · Cited by 493
Calcium signaling and neurodegenerative diseases
Bezprozvanny, I. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.001 · Cited by 469
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Protein aggregates in Huntington's disease
Arrasate, M., & Finkbeiner, S. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.013 · Cited by 383
Calpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration
Vosler, P. S., Brennan, C. S., & Chen, J. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8036-x · Cited by 382
Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis
Dasuri, K., Zhang, L., & Keller, J. N. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.016 · Cited by 371
Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., Sun, B., Gafni, J., Ellerby, L. M., Trottier, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075028 · Cited by 326
Self-citationRaymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
Mitochondria in Huntington's disease
Damiano, M., Galvan, L., Déglon, N., & Brouillet, E. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 284
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
“Proteolytic cleavage of specific proteins is the common denominator of many neurodegenerative diseases including huntingtin protein in Huntington’s disease [386,387], α-synuclein in Parkinson’s disease and Lewy body dementia [388], ataxins in cerebral ataxia [389,390], prion protein in prionosis [391,392] and tau”
BackgroundNguyen, T., Hamby, A., & Massa, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502177102 · Cited by 194
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment
Garg, S., Timm, T., Mandelkow, E.-M., Mandelkow, E., & Wang, Y. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.008 · Cited by 103
Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity
Pennuto, M., Palazzolo, I., & Poletti, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn412 · Cited by 82
Contribution of proteases to the hallmarks of aging and to age-related neurodegeneration
Rai, M., Curley, M., Coleman, Z., & Demontis, F. (2022) · Aging Cell · doi:10.1111/acel.13603 · Cited by 72
Primary cilia and autophagic dysfunction in Huntington’s disease
Kaliszewski, M., Knott, A. B., & Bossy-Wetzel, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.80 · Cited by 55
Metadata
- Authors
- Gafni, J., Hermel, E., Young, J. E., Wellington, C. L., Hayden, M. R., & Ellerby, L. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 279
- Issue
- 19
- Pages
- 20211-20220
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2067155896
- Cited by
- 281
- References
- 56
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.